Voss Capital LP Increases Stake in Actuate Therapeutics, Inc. $ACTU

Key Points

Error: Response status code does not indicate success: 429 (Too Many Requests).

Voss Capital LP raised its holdings in Actuate Therapeutics, Inc. (NASDAQ:ACTU - Free Report) by 157.7% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 142,381 shares of the company's stock after buying an additional 87,135 shares during the period. Voss Capital LP owned about 0.73% of Actuate Therapeutics worth $964,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also recently made changes to their positions in the business. BIOS Capital Management LP purchased a new stake in Actuate Therapeutics during the fourth quarter worth about $78,753,000. Sigma Planning Corp increased its stake in shares of Actuate Therapeutics by 47.3% in the first quarter. Sigma Planning Corp now owns 23,675 shares of the company's stock worth $160,000 after purchasing an additional 7,600 shares in the last quarter. Mercer Global Advisors Inc. ADV purchased a new position in shares of Actuate Therapeutics in the fourth quarter worth about $130,000. Sfmg LLC purchased a new position in shares of Actuate Therapeutics in the first quarter worth about $74,000. Finally, OMERS ADMINISTRATION Corp purchased a new position in shares of Actuate Therapeutics in the fourth quarter worth about $84,000.

Actuate Therapeutics Price Performance

Shares of NASDAQ:ACTU traded up $0.70 during trading on Friday, hitting $8.36. The company's stock had a trading volume of 58,818 shares, compared to its average volume of 62,450. Actuate Therapeutics, Inc. has a 12 month low of $5.47 and a 12 month high of $11.99. The company has a 50-day moving average of $7.05 and a 200-day moving average of $7.92.

Actuate Therapeutics (NASDAQ:ACTU - Get Free Report) last released its earnings results on Thursday, August 14th. The company reported ($0.30) EPS for the quarter, missing analysts' consensus estimates of ($0.19) by ($0.11).

Insiders Place Their Bets

In other news, Director Equity Cof Lp Bios bought 71,428 shares of the firm's stock in a transaction on Friday, June 27th. The shares were bought at an average price of $7.00 per share, for a total transaction of $499,996.00. Following the purchase, the director owned 196,428 shares in the company, valued at approximately $1,374,996. The trade was a 57.14% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Aaron G.L. Fletcher bought 71,428 shares of the firm's stock in a transaction on Friday, June 27th. The shares were purchased at an average price of $7.00 per share, for a total transaction of $499,996.00. Following the purchase, the director owned 196,428 shares in the company, valued at $1,374,996. This trade represents a 57.14% increase in their position. The disclosure for this purchase can be found here. In the last 90 days, insiders have bought 214,284 shares of company stock worth $1,499,988. Company insiders own 69.34% of the company's stock.

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on the stock. Wall Street Zen lowered shares of Actuate Therapeutics from a "hold" rating to a "sell" rating in a research report on Friday. HC Wainwright reiterated a "buy" rating and set a $20.00 target price on shares of Actuate Therapeutics in a research report on Monday, August 18th. Two investment analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, the company currently has a consensus rating of "Buy" and an average price target of $20.50.

About Actuate Therapeutics

Actuate Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of cancers. The company's lead product candidate is Elraglusib Injection, a novel glycogen synthase kinase-3 inhibitor to treat metastatic pancreatic ductal adenocarcinoma. It also develops Elraglusib for the treatment of Ewing sarcoma, metastatic melanoma, and colorectal cancer.